iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific
01 Novembre 2023 - 1:24PM
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced
the expansion of its AI-powered technology stack with the launch of
ShieldTx, a patent-pending antibody masking technology designed to
enable specific, highly targeted antibody delivery to diseased
tissue without harming healthy tissue. By adding ShieldTx to its
Drug Discovery Platform, iBio uniquely integrates antibody
engineering and masking in one accelerated process to potentially
overcome the challenges of complex targets, safety, and
developability in next-generation antibody discovery and
development.
The Company used ShieldTx to develop masks for
its MUC16-targeted bispecific antibody (“Ab”) candidates, which
were previously developed using iBio’s patented Epitope Steering
and EngageTx™ AI Platforms. MUC16 is a well-known cancer
target often overexpressed in several types of solid tumors,
including ovarian, lung, and pancreatic cancers.
One of the main challenges of therapeutic
antibody discovery is drug targets are often expressed on both
healthy and diseased tissue, resulting in off-tissue side effects.
Scientists are increasingly turning to antibody masking to reduce
or eliminate these side effects. Masks deactivate Abs until they
encounter a specific enzyme only present in the target diseased
tissue. When masked Abs engage with this specific enzyme, the mask
is removed, and the antibody is activated. This approach reduces or
eliminates off-tissue side effects, enhances the therapeutic safety
range, and reduces the risk of an unwanted immune response of
bispecific Abs1. In an in vitro laboratory setting, iBio’s
specially designed MUC16 bispecific Abs were deactivated and then
reactivated, demonstrating successful application of the ShieldTx
technology.
Traditional masking techniques are complex
procedures and require the sequential optimization of antibody and
mask. This increases development time and risk by adding more steps
to a typically linear development and optimization process.
“Our technology aims to advance antibody masking
by fine-tuning both the mask and antibody in tandem using our
StableHu™ antibody optimizer and its mammalian display technology,”
said Matt Greving, Ph.D., VP & Head of Machine Learning &
Platform Technologies at iBio. “This potentially reduces repetitive
steps and may significantly boost the probability of success in
creating masked antibodies. ShieldTx can be applied to cancer
therapeutics, and potentially to autoimmune and inflammatory
diseases. iBio intends to use ShieldTx to further optimize its
current antibody candidates, particularly the bispecific TROP-2 x
CD3 molecules developed using our proprietary T-cell engager
antibody panel, EngageTx.”
“With 40% of approved antibodies working against
just 10 targets2, there is significant potential for therapeutic
development against additional new targets; but unfortunately,
these targets are often difficult and complex, and require new
technologies to optimize antibody discovery and development,” added
iBio’s Chief Executive Officer and Chief Scientific Officer, Martin
Brenner, DVM, Ph.D. “We are rapidly building an integrated
end-to-end platform incorporating the most innovative technologies
in machine learning, computational biology, and synthetic biology
to enable iBio and our partners to craft the next generation of
antibody-based therapeutics against difficult targets and modes of
action. ShieldTx is the latest example, following the launch of
EngageTx earlier this year.”
References
- Kavanaugh, W. M. Antibody prodrugs
for cancer. Expert Opinion on Biological Therapy
20, 163–171 (2020).
- Reference: Lyu, X. et al. The
global landscape of approved antibody therapies. Antibody
Therapeutics 5, 233–257 (2022).
About iBio, Inc.
iBio develops next-generation biopharmaceuticals
using computational biology and 3D-modeling of subdominant and
conformational epitopes, prospectively enabling the discovery of
new antibody treatments for hard-to-target cancers and other
diseases. iBio’s mission is to decrease drug failures, shorten drug
development timelines, and open up new frontiers against the most
promising targets. For more information, visit www.ibioinc.com.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release
constitute "forward-looking statements" within the meaning of the
federal securities laws. Words such as "may," "might," "will,"
"should," "believe," "expect," "anticipate," "estimate,"
"continue," "predict," "forecast," "project," "plan," "intend" or
similar expressions, or statements regarding intent, belief, or
current expectations, are forward-looking statements. These
forward-looking statements are based upon current estimates and
assumptions and include statements regarding ShieldTx potentially
increasing safety and developability of therapeutic antibodies for
difficult targets and modes of action, ShieldTx, enabling specific,
highly targeted antibody delivery to diseased tissue without
harming healthy tissue; the integration of antibody engineering and
masking in one accelerated process overcoming the challenges of
complex targets, safety, and developability in next-generation
antibody discovery and development; therapeutic development against
additional new targets; the Company’s technology advancing antibody
masking by fine-tuning both the mask and antibody in tandem using
its StableHu antibody optimizer and its mammalian display
technology; the Company’s technology reducing repetitive steps and
significantly boosting the probability of success in creating
masked antibodies; ShieldTx being applied to cancer therapeutics,
and to autoimmune and inflammatory diseases; the Company using
ShieldTx to further optimize its current antibody candidates,
particularly the bispecific TROP-2 x CD3 molecules developed using
the Company’s proprietary T-cell engager antibody panel, EngageTx.
While the Company believes these forward-looking statements are
reasonable, undue reliance should not be placed on any such
forward-looking statements, which are based on information
available to us on the date of this release. These forward-looking
statements are subject to various risks and uncertainties, many of
which are difficult to predict that could cause actual results to
differ materially from current expectations and assumptions from
those set forth or implied by any forward-looking statements.
Important factors that could cause actual results to differ
materially from current expectations include, among others, the
Company’s ability to generate successful results from ShieldTx and
its ability to increase safety and developability of therapeutic
antibodies for difficult targets and modes of action and enable
specific, highly targeted antibody delivery to diseased tissue
without harming healthy tissue, the ability of the Company’s
technology to advance antibody masking by fine-tuning both the mask
and antibody in tandem, the ability of the Company’s technology to
reduce repetitive steps and significantly boosting the probability
of success in creating masked antibodies, the ability to apply
ShieldTx to cancer therapeutics, and to autoimmune and inflammatory
diseases and to optimize its current antibody candidates, the
Company’s ability to continue to execute its growth strategy; its
ability to obtain regulatory approvals for commercialization of its
product candidates, or to comply with ongoing regulatory
requirements; regulatory limitations relating to its ability to
promote or commercialize its product candidates for specific
indications; acceptance of its product candidates in the
marketplace and the successful development, marketing or sale of
products; its ability to maintain its license agreements; the
continued maintenance and growth of its patent estate; its ability
to obtain or maintain the capital or grants necessary to fund its
research and development activities and whether the Company will
incur unforeseen expenses or liabilities or other market factors;
successful compliance with governmental regulations applicable to
its manufacturing facility; competition; its ability to retain its
key employees or maintain its NYSE American listing; and the other
factors discussed in the Company’s filings with the SEC including
the Company’s Annual Report on Form 10-K for the year ended June
30, 2023 and the Company’s subsequent filings with the SEC on Forms
10-Q and 8-K. The information in this release is provided only as
of the date of this release, and the Company undertakes no
obligation to update any forward-looking statements contained in
this release on account of new information, future events, or
otherwise, except as required by law.
Contacts:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580skilmer@ibioinc.com
Susan ThomasiBio, Inc.Media Relations(619)
540-9195Sthomas@ibioinc.com
Grafico Azioni iBio (AMEX:IBIO)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni iBio (AMEX:IBIO)
Storico
Da Mag 2023 a Mag 2024